About: Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study
Creator	Moreno, Santiago Jarrín, Inma Martínez, Esteban Polo, Rosa Arribas, Asunció N Díaz, ; Del Amo, Julia Herná, Miguel Ramó, José
Source	Medline; PMC
abstract	BACKGROUND: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations. OBJECTIVE: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. DESIGN: Cohort study. SETTING: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. PARTICIPANTS: 77 590 HIV-positive persons receiving ART. MEASUREMENTS: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction–confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. RESULTS: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. LIMITATION: Residual confounding by comorbid conditions cannot be completely excluded. CONCLUSION: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. PRIMARY FUNDING SOURCE: Instituto de Salud Carlos III and National Institutes of Health.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.7326/m20-3689
bibo:pmid	32589451
has license	no-cc
sha1sum (hex)	03310c9f2bd42109641d4d359a93e125bc80e284
schema:url	https://doi.org/10.7326/m20-3689
resource representing a document's title	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study
has PubMed Central identifier	PMC7394316
has PubMed identifier	32589451
schema:publication	Ann Intern Med
resource representing a document's body	covid:03310c9f2bd42109641d4d359a93e125bc80e284#body_text
is schema:about of	named entity 'NRTI' named entity 'describe' named entity 'COVID' named entity 'reverse transcriptase inhibitor' named entity 'Cohort Study' named entity 'infection' named entity 'Spain' named entity 'HIV-positive' named entity 'follow-up' named entity 'Madrid' named entity 'SARS-CoV-2' named entity 'Spain' named entity 'lamivudine' named entity 'HIV-positive' named entity 'efavirenz' named entity 'Stata' named entity 'immunomodulatory' named entity 'Wuhan' named entity 'COVID' named entity 'polymerase chain reaction' named entity 'antigen' named entity 'HIV' named entity 'COVID' named entity 'COVID-19' named entity 'HIV infection' named entity 'public health emergency' named entity 'HIV-positive' named entity 'HIV' named entity 'COVID' named entity 'HIV-positive' named entity 'COVID-19' named entity 'ABC' named entity 'SARS-CoV-2' named entity 'phosphorylated' named entity 'COVID' named entity 'HIV-positive' named entity 'TDF' named entity 'protease inhibitor' named entity 'immunologic response' named entity 'NRTIs' named entity 'COVID' named entity 'infection models' named entity 'cytokine' named entity 'COVID' named entity 'ICU' named entity 'COVID-19' named entity 'tenofovir disoproxil fumarate' named entity 'inflammatory cytokines' named entity 'pandemics' named entity 'older age' named entity 'extracellular' named entity 'Spain' named entity 'monotherapy' named entity 'IL-10' named entity 'HIV-positive' named entity '3TC' named entity 'diabetes mellitus' named entity 'HIV' named entity 'HIV-positive' named entity 'HIV' named entity 'monocytes' named entity 'Tenofovir' named entity '3TC' named entity 'IL-8' named entity 'COVID' named entity 'all-cause mortality' named entity 'COVID' named entity 'TDF' named entity 'infection' named entity 'molecular docking' named entity 'general population' named entity 'protease inhibitor' named entity 'natural killer cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software